Maftivimab

Maftivimab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	Zaire ebolavirus glycoprotein
Clinical data
Pronunciation	maf tiv' i mab
License data	US DailyMed: Maftivimab ;
Drug class	Monoclonal antibody
ATC code	None;
Identifiers
CAS Number	2135632-36-7 ;
UNII	KOP95331M4 ;
KEGG	D11450 ;
Chemical and physical data
Formula	C6368H9886N1706O2008S46
Molar mass	143947.83 g·mol−1

Last updated May 30, 2025

Maftivimab is a Zaire ebolavirus glycoprotein-directed human monoclonal antibody that is part of the fixed-dose combination atoltivimab/maftivimab/odesivimab that is used for the treatment of Zaire ebolavirus (Ebola virus).^[1]^[2]

References

↑ "FDA Approves First Treatment for Ebola Virus". U.S. Food and Drug Administration (FDA) (Press release). 14 October 2020. Archived from the original on 15 October 2020. Retrieved 14 October 2020. This article incorporates text from this source, which is in the public domain .
↑ "Regeneron's Antibody Cocktail REGN-EB3 (Inmazeb) is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus)". Regeneron Pharmaceuticals Inc. (Press release). 14 October 2020. Retrieved 14 October 2020.

External links

"Maftivimab". Drug Information Portal. U.S. National Library of Medicine.
"Statement on a nonproprietary name adopted by the USAN Council USAN (FG-103) Maftivimab" (PDF).

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[FDA_PR-1] "FDA Approves First Treatment for Ebola Virus". U.S. Food and Drug Administration (FDA) (Press release). 14 October 2020. Archived from the original on 15 October 2020. Retrieved 14 October 2020. This article incorporates text from this source, which is in the public domain .

[2] "Regeneron's Antibody Cocktail REGN-EB3 (Inmazeb) is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus)". Regeneron Pharmaceuticals Inc. (Press release). 14 October 2020. Retrieved 14 October 2020.

[1]

[2]